FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test

The goal of this clinical trial is to prove that the RECAP test is capable of selecting advanced breast cancer patients sensitive for treatment with the PARP inhibitor talazoparib. Participants will undergo an ultrasound-guided biopsy and a blood withdrawal. Homologous Recombination (HR) deficient patients (approximately 30%) can start talazoparib treatment until progression of the disease or unacceptable side-effects and their response will be evaluated.

Trial Details

NCT ID
NCT06193525
Phase
PHASE2
Sponsor
Erasmus Medical Center
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Talazoparib
Locations (sample)
  • Leiden, South Holland, Netherlands|52.15833,4.49306
  • Rotterdam, South Holland, Netherlands|51.9225,4.47917
  • Groningen, Netherlands|53.21917,6.56667

Key Eligibility Criteria

  • WHO performance status 0-2
  • Locally advanced breast cancer without options for treatment with curative intent or metastatic breast cancer
  • Objective progressive disease (PD) according to RECIST within 4 months prior to study entry
  • The breast cancer must be either

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →